{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:46:35Z","timestamp":1776919595306,"version":"3.51.2"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["HHSN-271-2008-00025-C"],"award-info":[{"award-number":["HHSN-271-2008-00025-C"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1828399"],"award-info":[{"award-number":["1828399"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bmcl.2025.130328","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:30:01Z","timestamp":1751916601000},"page":"130328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis and evaluation of aporphinoid 5-HT7AR ligands as inhibitors of PC3 prostate cancer cell growth"],"prefix":"10.1016","volume":"128","author":[{"given":"Daniel","family":"Okpattah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anupam","family":"Karki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naga V.K.","family":"Pillarsetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne W.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.bmcl.2025.130328_bb0005","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130328_bb0010","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130328_bb0015","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.bmcl.2025.130328_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122653","article-title":"Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications","volume":"9","author":"Aurilio","year":"2020","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.bmcl.2025.130328_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130328_bb0030","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmcl.2025.130328_bb0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13041-014-0049-y","article-title":"How much do we know about the coupling of G-proteins to serotonin receptors?","volume":"7","author":"Giulietti","year":"2014","journal-title":"Mol Brain"},{"issue":"15","key":"10.1016\/j.bmcl.2025.130328_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115578","article-title":"Structural manipulation of aporphines via C10 nitrogenation leads to the identification of new 5-HT(7A)R ligands","volume":"28","author":"Karki","year":"2020","journal-title":"Bioorg Med Chem"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130328_bb0045","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00210-021-02051-z","article-title":"5-HT7 receptors as a new target for prostate cancer physiopathology and treatment: an experimental study on PC-3 cells and FFPE tissues","volume":"394","author":"Cinar","year":"2021","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130328_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115414","article-title":"Aporphines: a privileged scaffold in CNS drug discovery","volume":"256","author":"Zhu","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130328_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114335","article-title":"Discovery of eight alkaloids with D1 and D2 antagonist activity in leaves of Nelumbo nucifera Gaertn. Using FLIPR assays","volume":"278","author":"Zhou","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.bmcl.2025.130328_bb0060","doi-asserted-by":"crossref","DOI":"10.1515\/jcim-2023-0224","article-title":"Boldine: a narrative review of the bioactive compound with versatile biological and pharmacological potential","volume":"21","author":"Lamba","year":"2024","journal-title":"J Complement Integr Med"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130328_bb0065","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1021\/acschemneuro.1c00094","article-title":"The high affinity dopamine D(2) receptor agonist MCL-536: a new tool for studying dopaminergic contribution to neurological disorders","volume":"12","author":"Subburaju","year":"2021","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130328_bb0070","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/np500893h","article-title":"Semisynthetic studies on and biological evaluation of N-methyllaurotetanine analogues as ligands for 5-HT receptors","volume":"78","author":"Madapa","year":"2015","journal-title":"J Nat Prod"},{"issue":"14","key":"10.1016\/j.bmcl.2025.130328_bb0075","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1016\/j.bmc.2008.05.077","article-title":"Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines","volume":"16","author":"Liu","year":"2008","journal-title":"Bioorg Med Chem"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130328_bb0080","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bmcl.2014.02.066","article-title":"Evaluation of structural effects on 5-HT(2A) receptor antagonism by aporphines: identification of a new aporphine with 5-HT(2A) antagonist activity","volume":"24","author":"Ponnala","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"issue":"13","key":"10.1016\/j.bmcl.2025.130328_bb0085","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1021\/jm200347t","article-title":"Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson\u2019s agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile","volume":"54","author":"Zhang","year":"2011","journal-title":"J Med Chem"},{"issue":"15","key":"10.1016\/j.bmcl.2025.130328_bb0090","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1016\/j.bmcl.2007.05.057","article-title":"R-(\u2212)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands","volume":"17","author":"Si","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"10.1016\/j.bmcl.2025.130328_bb0095","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1021\/jm00011a002","article-title":"A-ring ortho-disubstituted aporphine derivatives as potential agonists or antagonists at serotonergic 5-HT1A receptors","volume":"38","author":"Cannon","year":"1995","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130328_bb0100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.bjp.0703357","article-title":"Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist","volume":"130","author":"Hagan","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130328_bb0105","first-page":"243","article-title":"Metastatic castration-resistant prostate cancer: insights on current therapy and promising experimental drugs","volume":"15","author":"Ferretti","year":"2023","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.bmcl.2025.130328_bb0110","first-page":"719","article-title":"Evaluation of cytotoxic and chemotherapeutic properties of boldine in breast cancer using in vitro and in vivo models","volume":"8","author":"Paydar","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130328_bb0115","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.3390\/molecules16032253","article-title":"In vitro cytotoxic evaluation of a novel phosphinyl derivative of boldine","volume":"16","author":"Thomet","year":"2011","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130328_bb0120","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/aps.2016.53","article-title":"Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach","volume":"37","author":"Qi","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bmcl.2025.130328_bb0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jare.2023.11.003","article-title":"Natural aporphine alkaloids: A comprehensive review of phytochemistry, pharmacokinetics, anticancer activities, and clinical application","volume":"63","author":"Sun","year":"2024","journal-title":"J Adv Res"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25002379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25002379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:19:29Z","timestamp":1776917969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25002379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"alternative-id":["S0960894X25002379"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130328","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of aporphinoid 5-HT7AR ligands as inhibitors of PC3 prostate cancer cell growth","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130328","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130328"}}